RxActuator adds veterinary industry veterans to advisory board

Journey Actuating Technologies, which does business as RxActuator, named John Corsale, Jr. and Greg Blair to its Board of Advisors as it pushes commercial adoption of its outpatient continuous-rate infusion system for companion animals. The move comes as the Raleigh company scales manufacturing, sales and partnerships ahead of a planned Series A raise.

Why it matters: - RxActuator is trying to make continuous-rate infusion care possible for stable pets recovering at home instead of staying overnight in the hospital. - The advisory board additions bring commercial experience that could help the company sell into corporate veterinary groups, specialty networks and academic hospitals. - The company is also building toward a Series A financing round, so commercial traction matters now.

What happened: - Journey Actuating Technologies, Inc., which does business as RxActuator, appointed John Corsale, Jr., DVM, MBA and Greg Blair to its Board of Advisors. - The company announced the additions on September 3, 2026, from Raleigh, North Carolina. - RxActuator said the two advisors bring more than four decades of combined veterinary operations and animal health commercial leadership. - The board additions come as RxActuator scales manufacturing, sales and clinical adoption of the RxActuator Mini-Infuser.

The details: - Dr. Corsale is founder of JCor Veterinary Consulting, founder and CEO of Vertex AI Systems, Inc. dba PetsOpia.AI, and a senior business advisor to Select Veterinary Health. - Dr. Corsale previously served as group vice president at VCA, where he led more than 130 hospitals across the Southeast for 15 years. - Dr. Corsale later became chief operating officer at Compassion-First Pet Hospitals and helped grow the network from 11 hospitals to 43 hospitals while revenue rose from $60 million to $300 million before the sale into NVA/Ethos. - Dr. Corsale also served in leadership roles at the University of Georgia College of Veterinary Medicine and Rocky Vista University College of Veterinary Medicine. - Dr. Corsale holds a DVM from The Ohio State University and an MBA from Wake Forest University. - Blair is global head of strategic partnerships and scouting at Dechra, where he leads companion-animal strategic partnerships and product and pipeline scouting. - Blair joined Dechra in 2026 after five years as senior vice president of business development and strategic planning at Zomedica and six years in business development at Elanco Animal Health. - Blair also held earlier roles at Johnson & Johnson, Intuitive Surgical and Enteromedics. - Blair holds bachelor’s degrees from Indiana University and an MBA from Duke University’s Fuqua School of Business. - RxActuator said both advisors will support commercial and partnership strategy as the company deepens penetration into corporate and multi-site veterinary groups, specialty and emergency hospital networks, and academic teaching hospitals. - The appointment follows the launch of RxActuator’s inaugural Clinical Advisory Board in June 2026. - The company said the board build-out is part of its clinical, technical and commercial governance ahead of planned Series A financing. - The RxActuator Mini-Infuser is described as the veterinary industry’s first outpatient continuous-rate infusion system. - The device uses a patented, water-activated polymer actuator to deliver a constant-rate infusion over 48 hours without batteries, software or programming. - The platform is supported by peer-reviewed publications, including a 2025 pancreatitis study in the Journal of Veterinary Internal Medicine that reported an 89.5% outpatient success rate. - RxActuator said the platform has been validated across more than 90 clinics in 26 U.S. states and three countries. - The company said active orders began after its March 2026 commercial relaunch. - Journey Actuating Technologies said it is developing intelligent infusion technology that connects drug delivery with real-world clinical outcomes. - The company is also executing a seed raise ahead of a targeted Series A. - RxActuator and Mini-Infuser are trademarks of Journey Actuating Technologies, Inc.

Between the lines: - The board appointments signal a push from product development toward broader hospital-system adoption. - Corsale brings deep operator experience inside multi-site veterinary networks, while Blair brings partnership and commercial deal-making experience from major animal health companies. - RxActuator is framing home-based infusion as a way to improve pet comfort, reduce staff burden and widen access to treatment for owners who might not afford hospitalization.

What's next: - RxActuator will lean on the new advisors as it tries to expand institutional sales and partnership channels. - The company will also keep building toward a Series A after its seed round. - Broader clinical and commercial adoption will likely depend on continued evidence, hospital-network uptake and manufacturing scale.